Special Issue "Aberrant Post-transcriptional and Translational Regulation in Carcinogenesis and Cancer Progression"

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Mechanisms of Diseases".

Deadline for manuscript submissions: closed (25 August 2023) | Viewed by 125

Special Issue Editor

Department of Pathology, Harbin Medical University, Harbin 150081, China
Interests: cancer; cancer metastasis; cancer immunotherapy; cancer chemotherapy; chemoprevention

Special Issue Information

Dear Colleagues,

Cancer is seriously harmful to human health and is acknowledged as a complex disease. In recent years, with the development of molecular biology and sequencing technology, aberrant post-transcriptional and translational regulation, such as alternative splicing, alternative polyadenylation, cytoplasmic polyadenylation, deadenylation, mRNA epigenetic modification, ribosome heterogeneousness, and so on, have been found to play important roles in carcinogenesis and cancer progression. Several important regulators have been discovered; these results promote the understanding of post-transcriptional and translational regulation and contribute to the progress of basic research on cancer.

This Special Issue will highlight important scientific findings on post-transcriptional and translational regulation in carcinogenesis and cancer progression as well as recent advances in the field. We invite submissions of original publications, systematic reviews, and communications.

Prof. Dr. Xiaobo Li
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • carcinogenesis
  • cancer progression
  • post-transcriptional and translational regulation
  • cancer immunotherapy
  • cancer chemotherapy

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop